CS medica A/S engages in the research and development of medical cannabis. The firm distributes its treatment line and skincare products under the CANNASEN trademark. It operates through GalaxaPharma A/S and CANNORDIC A/S segments. The GalaxaPharma A/S segment distributes operations for marketing and sales direct to consumers, retailers, and e-tail. The CANNORDIC A/S segment research and development, establishing global business contracts, supply of CBD ingredients and production of finished products. global sale, to distributors, including Galaxa Pharma in the Nordic Region. The company was founded by Lone Henriksen and Gitte Lund Henriksen on August 7, 2011 and is headquartered in Copenhagen, Denmark.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company